Global Avanafil

Avanafil Comprehensive Study by Application (Young Age Patients, Old Age Patients), Forms (50 Mg Avanafil, 100 Mg Avanafil, 200 Mg Avanafil), Therapeutic Areas (Musculoskeletal, Nephrology, Rheumatology, Family Medicine, Urology), Distribution Channel (Online Stores, Offline Stores) Players and Region - Global Market Outlook to 2028

Avanafil Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Avanafil is also known as Stendra, is used to treat male sexual function problems. It helps to increase blood flow to the penis to help a man get and keep an erection. This does not protect against sexually against diseases including HIV, syphilis, hepatitis B. This medicine is taken by mouth with or without food. This medicine is taken 15 or 30 minutes before sexual activity. It is responsible for the degradation of cGMP, which produces smooth muscle relaxation in the corpus cavernosum and allows the inflow of blood.This growth is primarily driven by Increasing Investment in Research and Development .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitMillion Units
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Supplies sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as VIVUS Inc. (United States), Sanofi (France), Menarini Group (Italy), Auxilium Pharmaceuticals (United States), Endo International (Ireland), JW Pharmaceutical (South Korea), Sanofi (France), Novartis (Switzerland), Merck & Co. (United States), GlaxoSmithKline (United Kingdom), Allergan (Ireland), Johnson & Johnson (United States) and Pfizer (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In January 2020, Novartis successfully completed the acquisition of The Medicines Company, adding inclisiran, a first-in-class potential cholesterol-lowering treatment. As a result of the merger, the company becomes an indirect wholly-owned subsidiary of Novartis, and the company's stock is no longer traded on the NASDAQ Global Select Market.
In Jun 2019, Acerus Pharmaceuticals Corporation announced health Canada completed the initial screening process for the new drug submission for avanafil. The company mentioned that this product will become a key growth driver for their Canadian men’s health franchise alongside NATESTO.The global Avanafil market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability.

Influencing Trend:
Increase Sale from E-Store

Market Growth Drivers:
Increasing Investment in Research and Development, Increase Number of Laboratories in Merging Countries and Increase Generality of Nephrology

Challenges:
It Has Side Effects Such As Headache, Flushing, or Dizziness and This Medicine Effects Majorly To Heart Patients

Restraints:
High Cost of Implantable Devices, Limited Awareness, and Hesitation for Taking Treatment

Opportunities:
High Growth Potential from Young Age People, Due To High Adoption Rate from Developed Countries

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Avanafil Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Avanafil Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Avanafil players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Avanafil Study Sheds Light on
— The Avanafil Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Avanafil industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Avanafil industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Young Age Patients
  • Old Age Patients
By Forms
  • 50 Mg Avanafil
  • 100 Mg Avanafil
  • 200 Mg Avanafil

By Therapeutic Areas
  • Musculoskeletal
  • Nephrology
  • Rheumatology
  • Family Medicine
  • Urology

By Distribution Channel
  • Online Stores
  • Offline Stores

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Investment in Research and Development
      • 3.2.2. Increase Number of Laboratories in Merging Countries
      • 3.2.3. Increase Generality of Nephrology
    • 3.3. Market Challenges
      • 3.3.1. It Has Side Effects Such As Headache, Flushing, or Dizziness
      • 3.3.2. This Medicine Effects Majorly To Heart Patients
    • 3.4. Market Trends
      • 3.4.1. Increase Sale from E-Store
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Avanafil, by Application, Forms, Therapeutic Areas, Distribution Channel and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Avanafil (Value)
      • 5.2.1. Global Avanafil by: Application (Value)
        • 5.2.1.1. Young Age Patients
        • 5.2.1.2. Old Age Patients
      • 5.2.2. Global Avanafil by: Forms (Value)
        • 5.2.2.1. 50 Mg Avanafil
        • 5.2.2.2. 100 Mg Avanafil
        • 5.2.2.3. 200 Mg Avanafil
      • 5.2.3. Global Avanafil by: Therapeutic Areas (Value)
        • 5.2.3.1. Musculoskeletal
        • 5.2.3.2. Nephrology
        • 5.2.3.3. Rheumatology
        • 5.2.3.4. Family Medicine
        • 5.2.3.5. Urology
      • 5.2.4. Global Avanafil by: Distribution Channel (Value)
        • 5.2.4.1. Online Stores
        • 5.2.4.2. Offline Stores
      • 5.2.5. Global Avanafil Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Avanafil (Volume)
      • 5.3.1. Global Avanafil by: Application (Volume)
        • 5.3.1.1. Young Age Patients
        • 5.3.1.2. Old Age Patients
      • 5.3.2. Global Avanafil by: Forms (Volume)
        • 5.3.2.1. 50 Mg Avanafil
        • 5.3.2.2. 100 Mg Avanafil
        • 5.3.2.3. 200 Mg Avanafil
      • 5.3.3. Global Avanafil by: Therapeutic Areas (Volume)
        • 5.3.3.1. Musculoskeletal
        • 5.3.3.2. Nephrology
        • 5.3.3.3. Rheumatology
        • 5.3.3.4. Family Medicine
        • 5.3.3.5. Urology
      • 5.3.4. Global Avanafil by: Distribution Channel (Volume)
        • 5.3.4.1. Online Stores
        • 5.3.4.2. Offline Stores
      • 5.3.5. Global Avanafil Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Avanafil (Price)
  • 6. Avanafil: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. VIVUS Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Menarini Group (Italy)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Auxilium Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Endo International (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. JW Pharmaceutical (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Allergan (Ireland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Johnson & Johnson (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Pfizer (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Avanafil Sale, by Application, Forms, Therapeutic Areas, Distribution Channel and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Avanafil (Value)
      • 7.2.1. Global Avanafil by: Application (Value)
        • 7.2.1.1. Young Age Patients
        • 7.2.1.2. Old Age Patients
      • 7.2.2. Global Avanafil by: Forms (Value)
        • 7.2.2.1. 50 Mg Avanafil
        • 7.2.2.2. 100 Mg Avanafil
        • 7.2.2.3. 200 Mg Avanafil
      • 7.2.3. Global Avanafil by: Therapeutic Areas (Value)
        • 7.2.3.1. Musculoskeletal
        • 7.2.3.2. Nephrology
        • 7.2.3.3. Rheumatology
        • 7.2.3.4. Family Medicine
        • 7.2.3.5. Urology
      • 7.2.4. Global Avanafil by: Distribution Channel (Value)
        • 7.2.4.1. Online Stores
        • 7.2.4.2. Offline Stores
      • 7.2.5. Global Avanafil Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Avanafil (Volume)
      • 7.3.1. Global Avanafil by: Application (Volume)
        • 7.3.1.1. Young Age Patients
        • 7.3.1.2. Old Age Patients
      • 7.3.2. Global Avanafil by: Forms (Volume)
        • 7.3.2.1. 50 Mg Avanafil
        • 7.3.2.2. 100 Mg Avanafil
        • 7.3.2.3. 200 Mg Avanafil
      • 7.3.3. Global Avanafil by: Therapeutic Areas (Volume)
        • 7.3.3.1. Musculoskeletal
        • 7.3.3.2. Nephrology
        • 7.3.3.3. Rheumatology
        • 7.3.3.4. Family Medicine
        • 7.3.3.5. Urology
      • 7.3.4. Global Avanafil by: Distribution Channel (Volume)
        • 7.3.4.1. Online Stores
        • 7.3.4.2. Offline Stores
      • 7.3.5. Global Avanafil Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Avanafil (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Avanafil: by Application(USD Million)
  • Table 2. Avanafil Young Age Patients , by Region USD Million (2017-2022)
  • Table 3. Avanafil Old Age Patients , by Region USD Million (2017-2022)
  • Table 4. Avanafil: by Forms(USD Million)
  • Table 5. Avanafil 50 Mg Avanafil , by Region USD Million (2017-2022)
  • Table 6. Avanafil 100 Mg Avanafil , by Region USD Million (2017-2022)
  • Table 7. Avanafil 200 Mg Avanafil , by Region USD Million (2017-2022)
  • Table 8. Avanafil: by Therapeutic Areas(USD Million)
  • Table 9. Avanafil Musculoskeletal , by Region USD Million (2017-2022)
  • Table 10. Avanafil Nephrology , by Region USD Million (2017-2022)
  • Table 11. Avanafil Rheumatology , by Region USD Million (2017-2022)
  • Table 12. Avanafil Family Medicine , by Region USD Million (2017-2022)
  • Table 13. Avanafil Urology , by Region USD Million (2017-2022)
  • Table 14. Avanafil: by Distribution Channel(USD Million)
  • Table 15. Avanafil Online Stores , by Region USD Million (2017-2022)
  • Table 16. Avanafil Offline Stores , by Region USD Million (2017-2022)
  • Table 17. South America Avanafil, by Country USD Million (2017-2022)
  • Table 18. South America Avanafil, by Application USD Million (2017-2022)
  • Table 19. South America Avanafil, by Forms USD Million (2017-2022)
  • Table 20. South America Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 21. South America Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 22. Brazil Avanafil, by Application USD Million (2017-2022)
  • Table 23. Brazil Avanafil, by Forms USD Million (2017-2022)
  • Table 24. Brazil Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 25. Brazil Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 26. Argentina Avanafil, by Application USD Million (2017-2022)
  • Table 27. Argentina Avanafil, by Forms USD Million (2017-2022)
  • Table 28. Argentina Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 29. Argentina Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 30. Rest of South America Avanafil, by Application USD Million (2017-2022)
  • Table 31. Rest of South America Avanafil, by Forms USD Million (2017-2022)
  • Table 32. Rest of South America Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 33. Rest of South America Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 34. Asia Pacific Avanafil, by Country USD Million (2017-2022)
  • Table 35. Asia Pacific Avanafil, by Application USD Million (2017-2022)
  • Table 36. Asia Pacific Avanafil, by Forms USD Million (2017-2022)
  • Table 37. Asia Pacific Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 38. Asia Pacific Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 39. China Avanafil, by Application USD Million (2017-2022)
  • Table 40. China Avanafil, by Forms USD Million (2017-2022)
  • Table 41. China Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 42. China Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 43. Japan Avanafil, by Application USD Million (2017-2022)
  • Table 44. Japan Avanafil, by Forms USD Million (2017-2022)
  • Table 45. Japan Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 46. Japan Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 47. India Avanafil, by Application USD Million (2017-2022)
  • Table 48. India Avanafil, by Forms USD Million (2017-2022)
  • Table 49. India Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 50. India Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 51. South Korea Avanafil, by Application USD Million (2017-2022)
  • Table 52. South Korea Avanafil, by Forms USD Million (2017-2022)
  • Table 53. South Korea Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 54. South Korea Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 55. Taiwan Avanafil, by Application USD Million (2017-2022)
  • Table 56. Taiwan Avanafil, by Forms USD Million (2017-2022)
  • Table 57. Taiwan Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 58. Taiwan Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 59. Australia Avanafil, by Application USD Million (2017-2022)
  • Table 60. Australia Avanafil, by Forms USD Million (2017-2022)
  • Table 61. Australia Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 62. Australia Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Avanafil, by Application USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Avanafil, by Forms USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 67. Europe Avanafil, by Country USD Million (2017-2022)
  • Table 68. Europe Avanafil, by Application USD Million (2017-2022)
  • Table 69. Europe Avanafil, by Forms USD Million (2017-2022)
  • Table 70. Europe Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 71. Europe Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 72. Germany Avanafil, by Application USD Million (2017-2022)
  • Table 73. Germany Avanafil, by Forms USD Million (2017-2022)
  • Table 74. Germany Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 75. Germany Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 76. France Avanafil, by Application USD Million (2017-2022)
  • Table 77. France Avanafil, by Forms USD Million (2017-2022)
  • Table 78. France Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 79. France Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 80. Italy Avanafil, by Application USD Million (2017-2022)
  • Table 81. Italy Avanafil, by Forms USD Million (2017-2022)
  • Table 82. Italy Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 83. Italy Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 84. United Kingdom Avanafil, by Application USD Million (2017-2022)
  • Table 85. United Kingdom Avanafil, by Forms USD Million (2017-2022)
  • Table 86. United Kingdom Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 87. United Kingdom Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 88. Netherlands Avanafil, by Application USD Million (2017-2022)
  • Table 89. Netherlands Avanafil, by Forms USD Million (2017-2022)
  • Table 90. Netherlands Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 91. Netherlands Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 92. Rest of Europe Avanafil, by Application USD Million (2017-2022)
  • Table 93. Rest of Europe Avanafil, by Forms USD Million (2017-2022)
  • Table 94. Rest of Europe Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 95. Rest of Europe Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 96. MEA Avanafil, by Country USD Million (2017-2022)
  • Table 97. MEA Avanafil, by Application USD Million (2017-2022)
  • Table 98. MEA Avanafil, by Forms USD Million (2017-2022)
  • Table 99. MEA Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 100. MEA Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 101. Middle East Avanafil, by Application USD Million (2017-2022)
  • Table 102. Middle East Avanafil, by Forms USD Million (2017-2022)
  • Table 103. Middle East Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 104. Middle East Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 105. Africa Avanafil, by Application USD Million (2017-2022)
  • Table 106. Africa Avanafil, by Forms USD Million (2017-2022)
  • Table 107. Africa Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 108. Africa Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 109. North America Avanafil, by Country USD Million (2017-2022)
  • Table 110. North America Avanafil, by Application USD Million (2017-2022)
  • Table 111. North America Avanafil, by Forms USD Million (2017-2022)
  • Table 112. North America Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 113. North America Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 114. United States Avanafil, by Application USD Million (2017-2022)
  • Table 115. United States Avanafil, by Forms USD Million (2017-2022)
  • Table 116. United States Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 117. United States Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 118. Canada Avanafil, by Application USD Million (2017-2022)
  • Table 119. Canada Avanafil, by Forms USD Million (2017-2022)
  • Table 120. Canada Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 121. Canada Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 122. Mexico Avanafil, by Application USD Million (2017-2022)
  • Table 123. Mexico Avanafil, by Forms USD Million (2017-2022)
  • Table 124. Mexico Avanafil, by Therapeutic Areas USD Million (2017-2022)
  • Table 125. Mexico Avanafil, by Distribution Channel USD Million (2017-2022)
  • Table 126. Avanafil Sales: by Application(Million Units)
  • Table 127. Avanafil Sales Young Age Patients , by Region Million Units (2017-2022)
  • Table 128. Avanafil Sales Old Age Patients , by Region Million Units (2017-2022)
  • Table 129. Avanafil Sales: by Forms(Million Units)
  • Table 130. Avanafil Sales 50 Mg Avanafil , by Region Million Units (2017-2022)
  • Table 131. Avanafil Sales 100 Mg Avanafil , by Region Million Units (2017-2022)
  • Table 132. Avanafil Sales 200 Mg Avanafil , by Region Million Units (2017-2022)
  • Table 133. Avanafil Sales: by Therapeutic Areas(Million Units)
  • Table 134. Avanafil Sales Musculoskeletal , by Region Million Units (2017-2022)
  • Table 135. Avanafil Sales Nephrology , by Region Million Units (2017-2022)
  • Table 136. Avanafil Sales Rheumatology , by Region Million Units (2017-2022)
  • Table 137. Avanafil Sales Family Medicine , by Region Million Units (2017-2022)
  • Table 138. Avanafil Sales Urology , by Region Million Units (2017-2022)
  • Table 139. Avanafil Sales: by Distribution Channel(Million Units)
  • Table 140. Avanafil Sales Online Stores , by Region Million Units (2017-2022)
  • Table 141. Avanafil Sales Offline Stores , by Region Million Units (2017-2022)
  • Table 142. South America Avanafil Sales, by Country Million Units (2017-2022)
  • Table 143. South America Avanafil Sales, by Application Million Units (2017-2022)
  • Table 144. South America Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 145. South America Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 146. South America Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 147. Brazil Avanafil Sales, by Application Million Units (2017-2022)
  • Table 148. Brazil Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 149. Brazil Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 150. Brazil Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 151. Argentina Avanafil Sales, by Application Million Units (2017-2022)
  • Table 152. Argentina Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 153. Argentina Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 154. Argentina Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 155. Rest of South America Avanafil Sales, by Application Million Units (2017-2022)
  • Table 156. Rest of South America Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 157. Rest of South America Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 158. Rest of South America Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 159. Asia Pacific Avanafil Sales, by Country Million Units (2017-2022)
  • Table 160. Asia Pacific Avanafil Sales, by Application Million Units (2017-2022)
  • Table 161. Asia Pacific Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 162. Asia Pacific Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 163. Asia Pacific Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 164. China Avanafil Sales, by Application Million Units (2017-2022)
  • Table 165. China Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 166. China Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 167. China Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 168. Japan Avanafil Sales, by Application Million Units (2017-2022)
  • Table 169. Japan Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 170. Japan Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 171. Japan Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 172. India Avanafil Sales, by Application Million Units (2017-2022)
  • Table 173. India Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 174. India Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 175. India Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 176. South Korea Avanafil Sales, by Application Million Units (2017-2022)
  • Table 177. South Korea Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 178. South Korea Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 179. South Korea Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 180. Taiwan Avanafil Sales, by Application Million Units (2017-2022)
  • Table 181. Taiwan Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 182. Taiwan Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 183. Taiwan Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 184. Australia Avanafil Sales, by Application Million Units (2017-2022)
  • Table 185. Australia Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 186. Australia Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 187. Australia Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 188. Rest of Asia-Pacific Avanafil Sales, by Application Million Units (2017-2022)
  • Table 189. Rest of Asia-Pacific Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 190. Rest of Asia-Pacific Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 191. Rest of Asia-Pacific Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 192. Europe Avanafil Sales, by Country Million Units (2017-2022)
  • Table 193. Europe Avanafil Sales, by Application Million Units (2017-2022)
  • Table 194. Europe Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 195. Europe Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 196. Europe Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 197. Germany Avanafil Sales, by Application Million Units (2017-2022)
  • Table 198. Germany Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 199. Germany Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 200. Germany Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 201. France Avanafil Sales, by Application Million Units (2017-2022)
  • Table 202. France Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 203. France Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 204. France Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 205. Italy Avanafil Sales, by Application Million Units (2017-2022)
  • Table 206. Italy Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 207. Italy Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 208. Italy Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 209. United Kingdom Avanafil Sales, by Application Million Units (2017-2022)
  • Table 210. United Kingdom Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 211. United Kingdom Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 212. United Kingdom Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 213. Netherlands Avanafil Sales, by Application Million Units (2017-2022)
  • Table 214. Netherlands Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 215. Netherlands Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 216. Netherlands Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 217. Rest of Europe Avanafil Sales, by Application Million Units (2017-2022)
  • Table 218. Rest of Europe Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 219. Rest of Europe Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 220. Rest of Europe Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 221. MEA Avanafil Sales, by Country Million Units (2017-2022)
  • Table 222. MEA Avanafil Sales, by Application Million Units (2017-2022)
  • Table 223. MEA Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 224. MEA Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 225. MEA Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 226. Middle East Avanafil Sales, by Application Million Units (2017-2022)
  • Table 227. Middle East Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 228. Middle East Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 229. Middle East Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 230. Africa Avanafil Sales, by Application Million Units (2017-2022)
  • Table 231. Africa Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 232. Africa Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 233. Africa Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 234. North America Avanafil Sales, by Country Million Units (2017-2022)
  • Table 235. North America Avanafil Sales, by Application Million Units (2017-2022)
  • Table 236. North America Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 237. North America Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 238. North America Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 239. United States Avanafil Sales, by Application Million Units (2017-2022)
  • Table 240. United States Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 241. United States Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 242. United States Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 243. Canada Avanafil Sales, by Application Million Units (2017-2022)
  • Table 244. Canada Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 245. Canada Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 246. Canada Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 247. Mexico Avanafil Sales, by Application Million Units (2017-2022)
  • Table 248. Mexico Avanafil Sales, by Forms Million Units (2017-2022)
  • Table 249. Mexico Avanafil Sales, by Therapeutic Areas Million Units (2017-2022)
  • Table 250. Mexico Avanafil Sales, by Distribution Channel Million Units (2017-2022)
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Avanafil: by Application(USD Million)
  • Table 265. Avanafil Young Age Patients , by Region USD Million (2023-2028)
  • Table 266. Avanafil Old Age Patients , by Region USD Million (2023-2028)
  • Table 267. Avanafil: by Forms(USD Million)
  • Table 268. Avanafil 50 Mg Avanafil , by Region USD Million (2023-2028)
  • Table 269. Avanafil 100 Mg Avanafil , by Region USD Million (2023-2028)
  • Table 270. Avanafil 200 Mg Avanafil , by Region USD Million (2023-2028)
  • Table 271. Avanafil: by Therapeutic Areas(USD Million)
  • Table 272. Avanafil Musculoskeletal , by Region USD Million (2023-2028)
  • Table 273. Avanafil Nephrology , by Region USD Million (2023-2028)
  • Table 274. Avanafil Rheumatology , by Region USD Million (2023-2028)
  • Table 275. Avanafil Family Medicine , by Region USD Million (2023-2028)
  • Table 276. Avanafil Urology , by Region USD Million (2023-2028)
  • Table 277. Avanafil: by Distribution Channel(USD Million)
  • Table 278. Avanafil Online Stores , by Region USD Million (2023-2028)
  • Table 279. Avanafil Offline Stores , by Region USD Million (2023-2028)
  • Table 280. South America Avanafil, by Country USD Million (2023-2028)
  • Table 281. South America Avanafil, by Application USD Million (2023-2028)
  • Table 282. South America Avanafil, by Forms USD Million (2023-2028)
  • Table 283. South America Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 284. South America Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 285. Brazil Avanafil, by Application USD Million (2023-2028)
  • Table 286. Brazil Avanafil, by Forms USD Million (2023-2028)
  • Table 287. Brazil Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 288. Brazil Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 289. Argentina Avanafil, by Application USD Million (2023-2028)
  • Table 290. Argentina Avanafil, by Forms USD Million (2023-2028)
  • Table 291. Argentina Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 292. Argentina Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 293. Rest of South America Avanafil, by Application USD Million (2023-2028)
  • Table 294. Rest of South America Avanafil, by Forms USD Million (2023-2028)
  • Table 295. Rest of South America Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 296. Rest of South America Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 297. Asia Pacific Avanafil, by Country USD Million (2023-2028)
  • Table 298. Asia Pacific Avanafil, by Application USD Million (2023-2028)
  • Table 299. Asia Pacific Avanafil, by Forms USD Million (2023-2028)
  • Table 300. Asia Pacific Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 301. Asia Pacific Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 302. China Avanafil, by Application USD Million (2023-2028)
  • Table 303. China Avanafil, by Forms USD Million (2023-2028)
  • Table 304. China Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 305. China Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 306. Japan Avanafil, by Application USD Million (2023-2028)
  • Table 307. Japan Avanafil, by Forms USD Million (2023-2028)
  • Table 308. Japan Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 309. Japan Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 310. India Avanafil, by Application USD Million (2023-2028)
  • Table 311. India Avanafil, by Forms USD Million (2023-2028)
  • Table 312. India Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 313. India Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 314. South Korea Avanafil, by Application USD Million (2023-2028)
  • Table 315. South Korea Avanafil, by Forms USD Million (2023-2028)
  • Table 316. South Korea Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 317. South Korea Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 318. Taiwan Avanafil, by Application USD Million (2023-2028)
  • Table 319. Taiwan Avanafil, by Forms USD Million (2023-2028)
  • Table 320. Taiwan Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 321. Taiwan Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 322. Australia Avanafil, by Application USD Million (2023-2028)
  • Table 323. Australia Avanafil, by Forms USD Million (2023-2028)
  • Table 324. Australia Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 325. Australia Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 326. Rest of Asia-Pacific Avanafil, by Application USD Million (2023-2028)
  • Table 327. Rest of Asia-Pacific Avanafil, by Forms USD Million (2023-2028)
  • Table 328. Rest of Asia-Pacific Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 329. Rest of Asia-Pacific Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 330. Europe Avanafil, by Country USD Million (2023-2028)
  • Table 331. Europe Avanafil, by Application USD Million (2023-2028)
  • Table 332. Europe Avanafil, by Forms USD Million (2023-2028)
  • Table 333. Europe Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 334. Europe Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 335. Germany Avanafil, by Application USD Million (2023-2028)
  • Table 336. Germany Avanafil, by Forms USD Million (2023-2028)
  • Table 337. Germany Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 338. Germany Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 339. France Avanafil, by Application USD Million (2023-2028)
  • Table 340. France Avanafil, by Forms USD Million (2023-2028)
  • Table 341. France Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 342. France Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 343. Italy Avanafil, by Application USD Million (2023-2028)
  • Table 344. Italy Avanafil, by Forms USD Million (2023-2028)
  • Table 345. Italy Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 346. Italy Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 347. United Kingdom Avanafil, by Application USD Million (2023-2028)
  • Table 348. United Kingdom Avanafil, by Forms USD Million (2023-2028)
  • Table 349. United Kingdom Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 350. United Kingdom Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 351. Netherlands Avanafil, by Application USD Million (2023-2028)
  • Table 352. Netherlands Avanafil, by Forms USD Million (2023-2028)
  • Table 353. Netherlands Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 354. Netherlands Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 355. Rest of Europe Avanafil, by Application USD Million (2023-2028)
  • Table 356. Rest of Europe Avanafil, by Forms USD Million (2023-2028)
  • Table 357. Rest of Europe Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 358. Rest of Europe Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 359. MEA Avanafil, by Country USD Million (2023-2028)
  • Table 360. MEA Avanafil, by Application USD Million (2023-2028)
  • Table 361. MEA Avanafil, by Forms USD Million (2023-2028)
  • Table 362. MEA Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 363. MEA Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 364. Middle East Avanafil, by Application USD Million (2023-2028)
  • Table 365. Middle East Avanafil, by Forms USD Million (2023-2028)
  • Table 366. Middle East Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 367. Middle East Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 368. Africa Avanafil, by Application USD Million (2023-2028)
  • Table 369. Africa Avanafil, by Forms USD Million (2023-2028)
  • Table 370. Africa Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 371. Africa Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 372. North America Avanafil, by Country USD Million (2023-2028)
  • Table 373. North America Avanafil, by Application USD Million (2023-2028)
  • Table 374. North America Avanafil, by Forms USD Million (2023-2028)
  • Table 375. North America Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 376. North America Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 377. United States Avanafil, by Application USD Million (2023-2028)
  • Table 378. United States Avanafil, by Forms USD Million (2023-2028)
  • Table 379. United States Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 380. United States Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 381. Canada Avanafil, by Application USD Million (2023-2028)
  • Table 382. Canada Avanafil, by Forms USD Million (2023-2028)
  • Table 383. Canada Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 384. Canada Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 385. Mexico Avanafil, by Application USD Million (2023-2028)
  • Table 386. Mexico Avanafil, by Forms USD Million (2023-2028)
  • Table 387. Mexico Avanafil, by Therapeutic Areas USD Million (2023-2028)
  • Table 388. Mexico Avanafil, by Distribution Channel USD Million (2023-2028)
  • Table 389. Avanafil Sales: by Application(Million Units)
  • Table 390. Avanafil Sales Young Age Patients , by Region Million Units (2023-2028)
  • Table 391. Avanafil Sales Old Age Patients , by Region Million Units (2023-2028)
  • Table 392. Avanafil Sales: by Forms(Million Units)
  • Table 393. Avanafil Sales 50 Mg Avanafil , by Region Million Units (2023-2028)
  • Table 394. Avanafil Sales 100 Mg Avanafil , by Region Million Units (2023-2028)
  • Table 395. Avanafil Sales 200 Mg Avanafil , by Region Million Units (2023-2028)
  • Table 396. Avanafil Sales: by Therapeutic Areas(Million Units)
  • Table 397. Avanafil Sales Musculoskeletal , by Region Million Units (2023-2028)
  • Table 398. Avanafil Sales Nephrology , by Region Million Units (2023-2028)
  • Table 399. Avanafil Sales Rheumatology , by Region Million Units (2023-2028)
  • Table 400. Avanafil Sales Family Medicine , by Region Million Units (2023-2028)
  • Table 401. Avanafil Sales Urology , by Region Million Units (2023-2028)
  • Table 402. Avanafil Sales: by Distribution Channel(Million Units)
  • Table 403. Avanafil Sales Online Stores , by Region Million Units (2023-2028)
  • Table 404. Avanafil Sales Offline Stores , by Region Million Units (2023-2028)
  • Table 405. South America Avanafil Sales, by Country Million Units (2023-2028)
  • Table 406. South America Avanafil Sales, by Application Million Units (2023-2028)
  • Table 407. South America Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 408. South America Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 409. South America Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 410. Brazil Avanafil Sales, by Application Million Units (2023-2028)
  • Table 411. Brazil Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 412. Brazil Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 413. Brazil Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 414. Argentina Avanafil Sales, by Application Million Units (2023-2028)
  • Table 415. Argentina Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 416. Argentina Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 417. Argentina Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 418. Rest of South America Avanafil Sales, by Application Million Units (2023-2028)
  • Table 419. Rest of South America Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 420. Rest of South America Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 421. Rest of South America Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 422. Asia Pacific Avanafil Sales, by Country Million Units (2023-2028)
  • Table 423. Asia Pacific Avanafil Sales, by Application Million Units (2023-2028)
  • Table 424. Asia Pacific Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 425. Asia Pacific Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 426. Asia Pacific Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 427. China Avanafil Sales, by Application Million Units (2023-2028)
  • Table 428. China Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 429. China Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 430. China Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 431. Japan Avanafil Sales, by Application Million Units (2023-2028)
  • Table 432. Japan Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 433. Japan Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 434. Japan Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 435. India Avanafil Sales, by Application Million Units (2023-2028)
  • Table 436. India Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 437. India Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 438. India Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 439. South Korea Avanafil Sales, by Application Million Units (2023-2028)
  • Table 440. South Korea Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 441. South Korea Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 442. South Korea Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 443. Taiwan Avanafil Sales, by Application Million Units (2023-2028)
  • Table 444. Taiwan Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 445. Taiwan Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 446. Taiwan Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 447. Australia Avanafil Sales, by Application Million Units (2023-2028)
  • Table 448. Australia Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 449. Australia Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 450. Australia Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 451. Rest of Asia-Pacific Avanafil Sales, by Application Million Units (2023-2028)
  • Table 452. Rest of Asia-Pacific Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 453. Rest of Asia-Pacific Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 454. Rest of Asia-Pacific Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 455. Europe Avanafil Sales, by Country Million Units (2023-2028)
  • Table 456. Europe Avanafil Sales, by Application Million Units (2023-2028)
  • Table 457. Europe Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 458. Europe Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 459. Europe Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 460. Germany Avanafil Sales, by Application Million Units (2023-2028)
  • Table 461. Germany Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 462. Germany Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 463. Germany Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 464. France Avanafil Sales, by Application Million Units (2023-2028)
  • Table 465. France Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 466. France Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 467. France Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 468. Italy Avanafil Sales, by Application Million Units (2023-2028)
  • Table 469. Italy Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 470. Italy Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 471. Italy Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 472. United Kingdom Avanafil Sales, by Application Million Units (2023-2028)
  • Table 473. United Kingdom Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 474. United Kingdom Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 475. United Kingdom Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 476. Netherlands Avanafil Sales, by Application Million Units (2023-2028)
  • Table 477. Netherlands Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 478. Netherlands Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 479. Netherlands Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 480. Rest of Europe Avanafil Sales, by Application Million Units (2023-2028)
  • Table 481. Rest of Europe Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 482. Rest of Europe Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 483. Rest of Europe Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 484. MEA Avanafil Sales, by Country Million Units (2023-2028)
  • Table 485. MEA Avanafil Sales, by Application Million Units (2023-2028)
  • Table 486. MEA Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 487. MEA Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 488. MEA Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 489. Middle East Avanafil Sales, by Application Million Units (2023-2028)
  • Table 490. Middle East Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 491. Middle East Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 492. Middle East Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 493. Africa Avanafil Sales, by Application Million Units (2023-2028)
  • Table 494. Africa Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 495. Africa Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 496. Africa Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 497. North America Avanafil Sales, by Country Million Units (2023-2028)
  • Table 498. North America Avanafil Sales, by Application Million Units (2023-2028)
  • Table 499. North America Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 500. North America Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 501. North America Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 502. United States Avanafil Sales, by Application Million Units (2023-2028)
  • Table 503. United States Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 504. United States Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 505. United States Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 506. Canada Avanafil Sales, by Application Million Units (2023-2028)
  • Table 507. Canada Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 508. Canada Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 509. Canada Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 510. Mexico Avanafil Sales, by Application Million Units (2023-2028)
  • Table 511. Mexico Avanafil Sales, by Forms Million Units (2023-2028)
  • Table 512. Mexico Avanafil Sales, by Therapeutic Areas Million Units (2023-2028)
  • Table 513. Mexico Avanafil Sales, by Distribution Channel Million Units (2023-2028)
  • Table 514. Research Programs/Design for This Report
  • Table 515. Key Data Information from Secondary Sources
  • Table 516. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Avanafil: by Application USD Million (2017-2022)
  • Figure 5. Global Avanafil: by Forms USD Million (2017-2022)
  • Figure 6. Global Avanafil: by Therapeutic Areas USD Million (2017-2022)
  • Figure 7. Global Avanafil: by Distribution Channel USD Million (2017-2022)
  • Figure 8. South America Avanafil Share (%), by Country
  • Figure 9. Asia Pacific Avanafil Share (%), by Country
  • Figure 10. Europe Avanafil Share (%), by Country
  • Figure 11. MEA Avanafil Share (%), by Country
  • Figure 12. North America Avanafil Share (%), by Country
  • Figure 13. Global Avanafil: by Application Million Units (2017-2022)
  • Figure 14. Global Avanafil: by Forms Million Units (2017-2022)
  • Figure 15. Global Avanafil: by Therapeutic Areas Million Units (2017-2022)
  • Figure 16. Global Avanafil: by Distribution Channel Million Units (2017-2022)
  • Figure 17. South America Avanafil Share (%), by Country
  • Figure 18. Asia Pacific Avanafil Share (%), by Country
  • Figure 19. Europe Avanafil Share (%), by Country
  • Figure 20. MEA Avanafil Share (%), by Country
  • Figure 21. North America Avanafil Share (%), by Country
  • Figure 22. Global Avanafil share by Players 2022 (%)
  • Figure 23. Global Avanafil share by Players (Top 3) 2022(%)
  • Figure 24. Global Avanafil share by Players (Top 5) 2022(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. VIVUS Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. VIVUS Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi (France) Revenue: by Geography 2022
  • Figure 30. Menarini Group (Italy) Revenue, Net Income and Gross profit
  • Figure 31. Menarini Group (Italy) Revenue: by Geography 2022
  • Figure 32. Auxilium Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Auxilium Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 34. Endo International (Ireland) Revenue, Net Income and Gross profit
  • Figure 35. Endo International (Ireland) Revenue: by Geography 2022
  • Figure 36. JW Pharmaceutical (South Korea) Revenue, Net Income and Gross profit
  • Figure 37. JW Pharmaceutical (South Korea) Revenue: by Geography 2022
  • Figure 38. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 39. Sanofi (France) Revenue: by Geography 2022
  • Figure 40. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 41. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 42. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Merck & Co. (United States) Revenue: by Geography 2022
  • Figure 44. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 45. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 46. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 47. Allergan (Ireland) Revenue: by Geography 2022
  • Figure 48. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 49. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 50. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 51. Pfizer (United States) Revenue: by Geography 2022
  • Figure 52. Global Avanafil: by Application USD Million (2023-2028)
  • Figure 53. Global Avanafil: by Forms USD Million (2023-2028)
  • Figure 54. Global Avanafil: by Therapeutic Areas USD Million (2023-2028)
  • Figure 55. Global Avanafil: by Distribution Channel USD Million (2023-2028)
  • Figure 56. South America Avanafil Share (%), by Country
  • Figure 57. Asia Pacific Avanafil Share (%), by Country
  • Figure 58. Europe Avanafil Share (%), by Country
  • Figure 59. MEA Avanafil Share (%), by Country
  • Figure 60. North America Avanafil Share (%), by Country
  • Figure 61. Global Avanafil: by Application Million Units (2023-2028)
  • Figure 62. Global Avanafil: by Forms Million Units (2023-2028)
  • Figure 63. Global Avanafil: by Therapeutic Areas Million Units (2023-2028)
  • Figure 64. Global Avanafil: by Distribution Channel Million Units (2023-2028)
  • Figure 65. South America Avanafil Share (%), by Country
  • Figure 66. Asia Pacific Avanafil Share (%), by Country
  • Figure 67. Europe Avanafil Share (%), by Country
  • Figure 68. MEA Avanafil Share (%), by Country
  • Figure 69. North America Avanafil Share (%), by Country
List of companies from research coverage that are profiled in the study
  • VIVUS Inc. (United States)
  • Sanofi (France)
  • Menarini Group (Italy)
  • Auxilium Pharmaceuticals (United States)
  • Endo International (Ireland)
  • JW Pharmaceutical (South Korea)
  • Sanofi (France)
  • Novartis (Switzerland)
  • Merck & Co. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Allergan (Ireland)
  • Johnson & Johnson (United States)
  • Pfizer (United States)
Additional players considered in the study are as follows:
Aasraw Biochemical Technology Co., Ltd (China) , Aasraw Biochemical Technology Co., Ltd (India) , DEAFARMA (Italy)
Select User Access Type

Key Highlights of Report


Jun 2023 201 Pages 54 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Avanafil Quantitative research analysis
Global Avanafil Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Avanafil Market are VIVUS Inc. (United States), Sanofi (France), Menarini Group (Italy), Auxilium Pharmaceuticals (United States), Endo International (Ireland), JW Pharmaceutical (South Korea), Sanofi (France), Novartis (Switzerland), Merck & Co. (United States), GlaxoSmithKline (United Kingdom), Allergan (Ireland), Johnson & Johnson (United States) and Pfizer (United States) etc.
Young Age Patients segment in Global market to hold robust market share owing to "Increasing Investment in Research and Development ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Avanafil market throughout the forecasted period.

Know More About Global Avanafil Report?

Have a Query? Click Here

Other Related Reports

Medical Footwear Comprehensive Study by Type (Shoes & Boots, Sandals, Others {Slippers, Flip-flops, Insoles}), Application (Diabetic Shoes, Arthritis Shoes, Bunions & Hallux Valgus Shoes, Flat Feet S...
$ 3750
Benzocaine Comprehensive Study by Application (Cosmetics, Anesthetic, Others), Form (Spray, Gel, Ointment, Paste), Purity (98%, 99%) Players and Region - Global Market Outlook to 2030
$ 3500
Cleanroom Consumables Comprehensive Study by Type (Safety Consumables {Frocks, Boot Covers, Shoe Covers, Bouffants, Pants & Face Masks, Other}, Cleaning Consumables {Mops, Buckets, Wringers, Squeegee...
$ 3750
Surgical Mask Comprehensive Study by Type (Basic Surgical Mask, Anti-Fog Surgical Mask, Fluid/Splash Resistant Surgical Mask, N95 Mask, Others), Application (Individual, Health Professionals, Industr...
$ 3650
Iron Supplement Comprehensive Study by Type (Tablet, Liquid), Application (Kids, Adult), End users (Food Industry, Pharmaceutical Industry, Chemical Industry), Form (Ferrous and Ferric iron salts (Fe...
$ 3650
Anti - Neoplastic Agents Comprehensive Study by Type (Alkylating and Alkylating-Like Agents, Antimetabolites, Antitumour Antibiotics, Plant Alkaloids, Miscellaneous Agents, Hormonal Agents), Applicat...
$ 3750